Climb Bio, Inc.
Close on Oct 19, 2026
- Market cap
- $740.98M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | Before market open | – | $-0.18 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | Before market open | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 5, 2026 | Before market open | – | $-0.26 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | Before market open | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 12, 2025 | Before market open | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 14, 2025 | Before market open | – | $-0.31 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 25, 2025 | During market hours | – | $-0.13 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | During market hours | – | $-0.13 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 14, 2024 | Before market open | – | $-1.81 | – |
| Q2 FY2023 Ended Jun 30, 2023 | Jul 20, 2023 | Before market open | – | – | – |
| Q1 FY2023 Ended Mar 31, 2023 | May 11, 2023 | During market hours | – | $-0.84 | – |
Press releases
Announcements Climb Bio filed with the SEC
Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy
Regulation FD disclosure · EX-99.1 to Form 8-K
Phase 1 Results September 3, 2026 Exhibit 99.2
Regulation FD disclosure · EX-99.2 to Form 8-K
Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Climb Bio Hosts Budoprutug R&D Spotlight Event Highlighting Topline Subcutaneous Formulation Data,
Regulation FD disclosure · EX-99.1 to Form 8-K
R&D Spotlight: Budoprutug and the
Regulation FD disclosure · EX-99.2 to Form 8-K
Climb Bio, Inc. Announces $110.0 Million Private Placement
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
IN THE SUPERIOR COURT OF THE STATE OF DELAWARE
Other events · EX-99.1 to Form 8-K
Climb Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Climb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgAN
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
R&D Spotlight: CLYM116 and the
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Climb Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Climb Bio Reports Fourth Quarter and Year-End 2024 Financial
Material agreement · Results of operations · EX-99.1 to Form 8-K
Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights
Results of operations · Other events · EX-99.1 to Form 8-K
UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENTS OF OPERATIONS
Results of operations · Other events · EX-99.2 to Form 8-K
Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Eliem Therapeutics Reports Second Quarter Financial Results
Results of operations · EX-99.1 to Form 8-K
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million
Material agreement · Acquisition or disposition completed · Unregistered share sale · Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Description of the Acquired Tenet Business
Material agreement · Acquisition or disposition completed · Unregistered share sale · Executive or director change · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Risk Factors Related to the Acquired Tenet Business and the Company Post-Closing
Material agreement · Acquisition or disposition completed · Unregistered share sale · Executive or director change · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
FOR BEST-IN-CLASS THERAPIES TO TREAT AUTOANTIBODY-MEDIATED DISEASES April 11, 2024 Exhibit 99.2
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
Eliem Tx / Tenet Medicines Acquisition Update Conference Call Script
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.3 to Form 8-K
Eliem Therapeutics Announces Plans to Explore Strategic Alternatives
Results of operations · Other events · EX-99.1 to Form 8-K
Eliem Therapeutics Reports First Quarter Financial Results and Business Highlights
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Clinical Stage Neurology Company Focused on Neuronal Excitability Disorders Corporate Presentation | May 2023
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Eliem Therapeutics Reports Fourth Quarter and Year-End Financial Results and Business Highlights
Results of operations · EX-99 to Form 8-K
Eliem Therapeutics Provides Strategic Update and Announces Leadership Transition
Results of operations · Exit or restructuring costs · Executive or director change · Other events · EX-99.1 to Form 8-K
Eliem Therapeutics Reports Third Quarter Financial and Business Highlights
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Clinical Stage Neurology Company Focused on Neuronal Excitability Disorders Corporate Presentation | November 14, 2022
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Eliem Therapeutics Provides Update on Pipeline Progress
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Excitability Disorders Corporate Presentation | October 5, 2022
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Eliem Therapeutics Reports Second Quarter Financial and Business Highlights
Results of operations · EX-99.1 to Form 8-K
Eliem Therapeutics Reports First Quarter Financial and Business Highlights
Results of operations · EX-99.1 to Form 8-K
Clinical Stage Neurology Company Focused on Neuronal Excitability Disorders Corporate Presentation |
Regulation FD disclosure · EX-99.1 to Form 8-K
Eliem Therapeutics Reports Fourth Quarter and Year-End Financial and Business Highlights
Results of operations · EX-99.1 to Form 8-K